Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] How can sponsors keep pace with this rapidly growing market and avoid costly delays that can threaten critical timelines?
Explore the analysis of a recent industry study examining sponsors’ most common roadblocks in cell and gene therapy development and the technology solutions that can help overcome them.
You’ll discover insights like:
1. Biopharma Dive, 5 questions facing gene therapy in 2023 (2023)
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific